LLY Gets Headache Relief, XENE Abuzz, 3rd Time's A Charm For PFE's Epogen Biosim

Today's Daily Dose brings you news about FDA approval of the first and only biosimilar erythropoiesis-stimulating agent in the U.S., Titan Pharma's better-than-expected Q1 results; Sol-Gel's clinical trial catalysts; Xenon Pharma's positive phase I interim data of epilepsy drug candidate XEN1101, and Lilly's phase III data of migraine drug candidate Galcanezumab.

from RTT - Biotech https://ift.tt/2Io9srW
via IFTTT